慢性HBV感染不同疾病状态治疗策略选择与获益评价

doi:10.3969/j.issn.1672-5069.2023.05.001

Abstract

Sheng Qiuju, Dou Xiaoguang. Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection[J]. Journal of Practical Hepatology, 2023, 26(5): 609-611.

[1] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志, 2023, 26(3): S18-S39.
[2] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol, 2008, 48(2): 335-352.
[3] Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology, 2010, 51(2): 435-444.
[4] Duberg AS, Lybeck C, Falt A, et al. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: a national register study. HepatolCommun, 2022, 6(9): 2418-2430.
[5] Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 2017, 66(5):1444-1453.
[6] McMahon BJ, Nolen LD, Snowball M, et al. HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: the hepatitis B Alaska study. Hepatology, 2021, 74(6): 2965-2973.
[7] Campbell C, Wang T, McNaughton AL, et al. Risk factors for the development of hepatocellular carcinoma (HCC)in chronic hepatitis B virus (HBV)infection: a systematic review and meta-analysis. J Viral Hepat, 2021, 28(3): 493-507.
[8] Alshuwaykh O, Daugherty T, Cheung A, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy. HepatolCommun, 2022, 6(11): 3052-3061.
[9] Ferreira G, Stuurman AL, Horsmans Y, et al. Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink. Eur J GastroenterolHepatol, 2020, 32(1): 101-109.
[10] Chayanupatkul M,Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol, 2017, 66(2): 355-362.
[11] Singal AK, Salameh H, Kuo YK, et al. Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther, 2013, 38(2): 98-106.
[12] Russo FP, Zanetto A, Pinto E, et al. Hepatocellular carcinoma in chronic viral hepatitis: where do we stand? Int J Mol Sci, 2022, 23(1): 500.
[13] Choi J,Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol, 2019, 5(1): 30-36.
[14] Qi WQ, Zhang Q, Wang X, et al. Long-term clinical benefit of Peg-IFNα and NAs sequential anti-viral therapy on HBV related HCC. Neoplasma, 2021, 68(1): 200-207.
[15] Li SY, Li H, Xiong YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: a five-year observational cohort study. J Viral Hepat, 2017, 24(Suppl 1): 12-20.
[16] Liang KH, Hsu CW, Chang ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis, 2016, 213(6): 966-974.
[17] Ren P, Cao Z, Mo R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther, 2018, 18(10):1085-1094.

Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Dan, Ding Yang. Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 612-614.
[2]	Peng Zhen, Ning Huibin, Li Kuan, et al. Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 615-617.
[3]	Huang Baisheng, Ou Lanxin, Zhang Yinjie, et al. Diagnostic performance of FibroScan and GPR, APRI and FIB-4 for liver fibrosis evaluation in patients with chronic hepatitis B virus infection without serum alanine aminotransferase elevation [J]. Journal of Practical Hepatology, 2023, 26(5): 618-621.
[4]	Wu Yulong, Zhuang Jianqi, Liu Zhicheng, et al. Changes of serum HBV pgRNA levels in patients with chronic hepatitis B receiving nucleos(t)ide analogues treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 622-625.
[5]	Wang Yizhuo, Zhang Weiqi, Li Hong. A 3-year follow-up of patients with serum HBeAg-positive chronic hepatitis B after 48 to 72 week pegylated interferon α-2a treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 626-629.
[6]	Hao Anhua, Du Zhongcai, Zhou Lin, et al. Changes of liver stiffness measurement and S index in patients with chronic hepatitis B and their performance in evaluating liver fibrosis [J]. Journal of Practical Hepatology, 2023, 26(5): 630-633.
[7]	Liu Aihua, Fu Jian, Chen Xiaohong. Predicting performance of liver stiffness measurement and GGT/PLT ratio combination in judging liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(5): 634-637.
[8]	Zhou Keli, Lyu Xiaoli, Zhou Yang, et al. Concordance between liver biopsy,and the liver stiffness measurement and hemodynamic index combination for the diagnosis of hepatic fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(4): 480-483.
[9]	Tang Xinhua, Tang Huijing, Huang Chengjun, et al. Preventive effect of entecavir on anti-tuberculosis drug-induced liver injury in patients with pulmonary tuberculosis and serum HBeAg-positive high HBV loads [J]. Journal of Practical Hepatology, 2023, 26(4): 516-519.
[10]	Jiao Yubing, Li Ling, Huang Xinhui, et al. Impact of low-level viremia on prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after TACE therapy [J]. Journal of Practical Hepatology, 2023, 26(4): 548-551.
[11]	Liu Ying, Chen Dongmiao, Wang Congrong. Implications of serum adenosine deaminase, α-L-fucosidase and alpha fetoprotein-L3 levels in patients with chronic hepatitis B, liver cirrhosis and primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(4): 552-555.
[12]	Tao Zhenzhen, Wang Yongli, Sun Hongyan, et al.. Comparison of different Young's modulus determination by two-dimensional shear wave elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 328-331.
[13]	Zhao Jing, He Xiubo, Chen Jinhuan. Early diagnosis of significant liver fibrosis by liver shear wave elastography and GGT/PLT ratio in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 332-335.
[14]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[15]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.